Cilostazol is clinically used for the treatment of ischemic symptoms in patients with chronic peripheral arterial obstruction and for the secondary prevention of brain infarction. Recently, it has been reported that cilostazol has preventive effects on atherogenesis and decreased serum triglyceride in rodent models. There are, however, few reports on the evaluation of cilostazol using atherosclerotic rabbits, which have similar lipid metabolism to humans, and are used for investigating the lipid content in aorta and platelet aggregation under conditions of hyperlipidemia. Therefore, we evaluated the effect of cilostazol on the atherosclerosis and platelet aggregation in rabbits fed a normal diet or a cholesterol-containing diet supplemented with or without cilostazol. We evaluated the effects of cilostazol on the atherogenesis by measuring serum and aortic lipid content, and the lesion area after a 10-week treatment and the effect on platelet aggregation after 1- and 10-week treatment. From the lipid analyses, cilostazol significantly reduced the total cholesterol, triglyceride and phospholipids in serum, and moreover, the triglyceride content in the atherosclerotic aorta. Cilostazol significantly reduced the intimal atherosclerotic area. Platelet aggregation was enhanced in cholesterol-fed rabbits. Cilostazol significantly inhibited the platelet aggregation in rabbits fed both a normal diet and a high cholesterol diet. Cilostazol showed anti-atherosclerotic and anti-platelet effects in cholesterol-fed rabbits possibly due to the improvement of lipid metabolism and the attenuation of platelet activation. The results suggest that cilostazol is useful for prevention and treatment of atherothrombotic diseases with the lipid abnormalities.
Citation: Ito H, Uehara K, Matsumoto Y, Hashimoto A, Nagano C, Niimi M, et al. (2012) Cilostazol Inhibits Accumulation of Triglyceride in Aorta and Platelet Aggregation in Cholesterol-Fed Rabbits. PLoS ONE 7(6): e39374. https://doi.org/10.1371/journal.pone.0039374
Editor: Peter J. Lenting, Institut National de la Santé et de la Recherche Médicale, France
Received: January 19, 2012; Accepted: May 21, 2012; Published: June 22, 2012
Copyright: © 2012 Ito et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The authors have no support or funding to report.
Competing interests: The authors are researchers of the pharmaceutical company which produces and sells cilostazol. This does not alter the authors’ adherence to all the PLoS ONE policies on sharing data and materials.
According to the response-to-injury hypothesis, endothelial dysfunction triggers atherosclerosis progression . Platelets are activated and aggregated on the exposed subendothelial tissues when the endothelium is wounded in the atherosclerotic lesion. Atherosclerosis also progresses with an elevation of serum cholesterol, and platelets have been shown to be activated in patients and rabbits with hypercholesterolemia –. If the hypercholesterolemia continues for a long period, atherosclerosis progresses in major arteries, and eventually may result in cardiovascular diseases. Since platelets play a pivotal role in atherosclerosis progression, they represent a key target for anti-atherothrombotic therapy .
For the evaluation of platelet function in atherothrombotic diseases, platelet aggregation can be measured. However, the conventional light transmission method  is not suitable for the measurement of platelet aggregation under a hyperlipidemic condition because the chylous plasma hampers light transmission. As an alternative method, platelet aggregation can be measured using whole blood with impedance or screen filtration pressure (SFP) –. The SFP method has been demonstrated to be reproducible in addition to being easy to handle .
Cilostazol, a selective inhibitor of phosphodiesterase 3, is a vasodilating anti-platelet drug . It has been used for the treatment of ischemic symptoms in patients with chronic peripheral arterial obstruction and for the secondary prevention of brain infarction –. In experimental studies, cilostazol has been shown to prevent thrombus formation indicating its potent anti-thrombotic effect based on its inhibitory action towards platelet function –. Recently, it has been reported that cilostazol attenuated atherosclerosis in low density lipoprotein receptor knock out mice and Apo-E knock out mice –. Some reports indicated that cilostazol improved lipid metabolism. For example, cilostazol decreased serum triglyceride and increased the serum high-density lipoprotein cholesterol (HDL-C) in mice –, rats – and human –. In the present study, we analyzed for the first time, the serum lipoprotein from rabbits treated with cilostazol using high-performance liquid chromatography (HPLC).
Transgenic mice and rabbits have been extensively used as atherosclerosis-prone experimental animals. However, mice and rats are naturally deficient in cholesteryl ester transfer protein activity, unlike humans and rabbits. It is known that New Zealand White rabbits have low plasma total cholesterol concentrations, high cholesteryl ester transfer protein activity, low hepatic lipase activity, and lack an analogue of human apolipoprotein A-II, providing a unique system in which to assess the effects of human transgenes on plasma lipoproteins and atherosclerosis susceptibility –. Additionally, as the rabbits become hyperlipidemic by eating a high fat diet, it makes them an appropriate model to assess the effects of drugs for their potential use in the treatment of dyslipidemia.
In the present study, we evaluated whether cilostazol prevents atherogenesis and platelet aggregation in hypercholesterolemic rabbits as they have more similar pathologic characteristics to human atherosclerosis than mice.
Atherosclerotic Area and Aortic Lipids
The rate of the atherosclerotic area in the whole aorta in the control group was 44.4±13.6% and it was significantly attenuated by cilostazol treatment (28.8±10.3%, p = 0.0185) as shown in Figure 1. The reduction in atherosclerotic areas by cilostazol treatment was also significant in both the thoracic aorta (control : cilostazol, 48.4±12.2∶35.8±12.6%, p = 0.0443) and the abdominal aorta (control : cilostazol, 38.2±16.2∶17.6±12.6%, p = 0.0087). On the other hand, the triglyceride (TG) content in the cilostazol group was significantly lower than in the control group in the arch and the whole aorta (arch: 4.0±1.1 versus 2.0±0.4 mg/g, p = 0.006, whole: 3.5±1.3 versus 1.5±0.4 mg/g, p = 0.029) as shown in Figure 2. The total cholesterol (TC) contents in the cilostazol group tended to be lower than in the control group in the arch and the whole artery (arch: 45.8±14.2 versus 28.0±11.0 mg/g, p = 0.058, whole: 24.1±8.2 versus 14.4±5.7 mg/g, p = 0.062). The free cholesterol (FC) and phospholipid (PL) did not differ between the control and cilostazol groups in each region. The wet weights of the aortas showed no differences between the control group and cilostazol group.
Plaques areas in the aorta of a typical animal in each group are shown by black areas (A). Individual values in the control group are shown by closed triangles (previous study) and closed circles (present study) and those in the cilostazol group by opened triangles (previous study) and opened circles (present study) and the horizontal bars in each group represent the mean and the vertical bars are the SD (B). Control [n = 10], cilostazol [n = 10]. *: p<0.05, **: p<0.01 versus control by a two-way ANOVA.
Amounts of triglyceride (A), total cholesterol (B), free cholesterol (C) and phospholipid (D) in different regions of the aorta. Individual values of the control group are shown by closed columns and those of the cilostazol group by opened columns. Data represent means ± S.D. Control [n = 5], cilostazol [n = 5]. *: p<0.05, **: p<0.01 versus control by t-test.
The results of immunohistochemical staining of macrophages in the proximal ascending aorta are shown in Figure 3. The mean values of the macrophage-positive areas did not differ between the control group (1.32±0.71 mm2) and the cilostazol group (1.46±1.33 mm2). However, two of the five samples in the cilostazol group did not have a macrophage-positive area, although all samples in the control group had macrophages. Additionally, the same section was stained by the Elastica-van Gieson method. The ratio of intima/media thickness in the aorta when measured at the same location did not differ between the two groups (data not shown).
Cross sections of the proximal ascending aorta were stained by an anti-macrophage RAM11 antibody. The brown part represents the macrophage-positive area. Typical images are shown for the control and cilostazol groups. Two of the five samples in the cilostazol group were not stained by the RAM11 antibody (the right image of cilostazol), although all samples were stained in the control group.
Platelet aggregability was expressed as a platelet aggregatory threshold index (PATI) value which is the concentration of agonist required to cause 50% platelet aggregation. Thus, if the PATI value for a certain condition is high, it means that platelet aggregability is suppressed under that condition. The PATI value for the high cholesterol diet was significantly lower than that in a normal diet indicating that platelet aggregability was enhanced by high-cholesterol feeding (Figure 4-A). When rabbits were fed a normal diet, cilostazol significantly inhibited the platelet aggregation 1 week after drug treatment (Figure 4-B). Furthermore, cilostazol significantly prevented the platelet aggregation 1 week after drug treatment in rabbits fed a 0.5% cholesterol diet (Figure 4-C). The inhibitory effect of cilostazol was maintained 10 weeks after drug treatment. A significant linear correlation was observed between the serum TC concentrations and the PATI values prior to drug treatment (Figure 4-D, correlation coefficient: r = –0.6897, p<0.001).
Comparison of platelet aggregation between normal and hypercholesterolemic rabbits (A). Effect of cilostazol on platelet aggregation in normal rabbits (B) or hypercholesterolemic rabbits (C). The control group are shown by closed circles and the cilostazol group by open circles. Correlation between serum TC and PATI values (D). Normal rabbits are shown by closed triangles and hypercholesterolemic rabbits by open triangles. Data represent means ± S.D. Normal rabbit study: control [n = 8], cilostazol [n = 8], hypercholesterolemic rabbit study: control [n = 5], cilostazol [n = 5]. **: p<0.01 versus control by t-test. PATI: Platelet aggregatory threshold index, TC: total cholesterol, R: correlative rate.
Serum Lipids and Other Biomarkers
Changes in serum lipids and other biomarkers are shown in Table 1. Serum TC, TG and PL levels were gradually elevated until the 10th week in the control group fed the 0.5% cholesterol diet. The elevation of the serum lipids was significantly reduced by cilostazol treatment; TC: p = 0.0435, TG: p = 0.0105 and PL: p = 0.0144 (group*time interaction in repeated measures analysis of variances). Serum FC also increased in the control group and tended to be suppressed by cilostazol treatment (p = 0.1169, group*time). Serum HDL-C did not show any change in the control but increased in the cilostazol group from the 2nd week to the 4th week (p = 0.0239, group*time, p = 0.0361, group difference). Using serum glutamate oxaloacetate transaminase (GOT), glutamate pyruvate transaminase (GPT) and alkaline phosphatase (ALP) as indices of hepatic function no differences between the control and cilostazol groups were noted. Serum C-reactive protein (CRP), an index of inflammation, markedly increased until the 10th week although the CRP levels contained considerable individual variability. Cilostazol did not affect the elevation of serum CRP. By serum TG monitoring by HPLC, the high fat diet increased TG in very low-density lipoprotein and chylomicron fractions, and cilostazol reduced TG in the same fractions (Figure 5).
Lipoproteins in 10 week treatment serum samples were analyzed by HPLC. The mean value of the control group is shown by a red line and the cilostazol group by the blue line and the normal diet group by the green line. Control [n = 5], cilostazol [n = 5], normal diet [n = 3].
Serum Concentration of Cilostazol
Each morning, blood samples were collected to measure the cilostazol concentration in serum 1 hour after feeding. The serum concentrations of cilostazol were 256±86 ng/mL from rabbits fed a normal diet and 294±198 ng/mL from rabbits fed a high-cholesterol diet, approximately one-third of that normally obtained in the clinic.
The present study is the first to evaluate the effects of cilostazol on atherosclerosis and ex vivo platelet aggregation in hypercholesterolemic rabbits. We showed that cilostazol significantly reduced the atherosclerotic area and the serum TG and increased the serum HDL-C in addition to reducing TC and PL in hypercholesterolemic rabbits. Additionally, it is particularly worth noting that cilostazol significantly reduced the aortic TG in the rabbits although aortic lipids were not measured in the previous studies of atherosclerotic mice –. Cilostazol strongly reduced serum triglycerides with a slight increase in HDL-cholesterol after 2 and 4 weeks of treatment. The results agree well with the results from patients with peripheral arterial disease (PAD) –. Cilostazol may be more effective at reducing serum TG than increasing the HDL-C. Others have also reported that cilostazol reduced pro-atherogenic lipoproteins such as remnants-like particles, which is a strong contributor to cardiovascular risk, in the plasma of patients with PAD and/or type 2 diabetes –. Hirano et al. has reported that TG deposits were found in the cardiac arteries of a patient with cardiomyopathy , and the reduction of aortic TG content has clinical implication. Maeda et al. studied the effect of cilostazol on the TG secretion from the liver using an inhibitor of lipoprotein lipase in rats, and found that the rate of TG secretion was decreased by cilostazol . On the other hand, Tani et al. have demonstrated that cilostazol increased lipoprotein lipase activity, resulting in a decrease in serum TG levels in streptozotocin-induced diabetic rats . These cilostazol-induced actions might contribute to the reduction of serum TG in hypercholesterolemic rabbits. It is also known that pharmacological agents that increase intracellular cyclic AMP levels can enhance HDL3-mediated, sterol efflux from cholesterol-loaded human skin fibroblasts and bovine aortic endothelial cells . The mild elevation of HDL-C by cilostazol treatment noted in this study might be due to the same mode of action because cilostazol increases intracellular cyclic AMP levels by inhibiting phosphodiesterase 3. It is well-known that a high level of low-density lipoprotein cholesterol and a low level of HDL-C are principal risk factors for coronary heart disease and stroke –. Serum TG is also one of the principal risk factors for arterial thrombotic diseases –. Decreasing serum and aortic TG by cilostazol treatment may contribute to the prevention of the atherothrombotic diseases.
In contrast to the significant reduction in triglyceride content in the aorta, treatment with cilostazol did not show a statistically significant effect on the atherosclerotic area. We have investigated the anti-atherosclerotic effect of cilostazol by treatment in a dose-dependent manner (0.1, 0.3 and 1.0% cilostazol diet) in cholesterol-fed rabbits ahead of the present study, and we observed that a 0.3% cilostazol diet tended to reduce the atherosclerotic area. Therefore, in this study, we confirmed the reproducibility of the anti-atherosclerotic effect of cilostazol and examined in more detail the effects of cilostazol on serum lipids, aorta lipids, and platelet aggregation. The anti-atherosclerotic efficacy of cilostazol was analyzed using the combined results from the dual study. A significant linear correlation was observed between serum TG and aortic TG (correlation coefficient: r = 0.5745) but no correlation between serum CRP and aortic TG was noted. In addition, from the result obtained for the serum TG monitoring by HPLC, it was speculated that the reduction of triglyceride in both very low-density lipoprotein and chylomicron by cilostazol might contribute to the reduction of triglyceride accumulation in the aorta. Clarification of the mechanism of TG reduction by cilostazol requires further study. The evaluation of the atherosclerotic area is meaningful to detect whether the plaque is abundant or not. Actually, more plaques were observed on the thoracic aorta than on the abdominal aorta and the plaques were abundant around the arterial bifurcation. It is possible that irregular local shear stress might be involved in the plaque formation at such areas. The local shear stress is one of the important factors affecting platelet functions. Cilostazol inhibited the shear stress-induced platelet aggregation .
From the immunostaining analysis of the macrophages in the proximal ascending aorta, there was no difference between the macrophage-positive areas in the two groups. However, it may be a notable result that 2 of the 5 samples in the cilostazol group were not stained by the anti-macrophage antibody, while all samples were stained in the control group. Cilostazol inhibited the monocyte adhesion to endothelia activated by remnant lipoprotein . The results in this study might partially reflect the inhibitory effect of cilostazol on the monocyte adhesion. However, further study is warranted to elucidate the exact effect of cilostazol on macrophage accumulation in atherosclerotic plaques.
It has recently been reported that cilostazol inhibited the uptake of modified low-density lipoprotein cholesterol and foam cell formation in mouse peritoneal macrophages by reduction in the expression of scavenger receptors . Moreover, cilostazol has been shown to inhibit the proliferation of smooth muscle cells and protect from endothelial injury –. Monocyte adhesions to the endothelium and platelets are also prevented by cilostazol –. Thus, the pleiotropic effects of cilostazol, such as its anti-platelet, anti-atherosclerotic and anti-inflammatory actions may be important for preventing the progression of atherosclerotic disease.
The light transmission method has been generally used for the measurement of platelet aggregation. In this conventional method, the change in light transmission following addition of an agonist is traced as a parameter of platelet aggregation, where the light transmission of the platelet-poor plasma is set at 100% and that of the platelet-rich plasma as 0%. Therefore, the method is unsuitable for measuring platelet aggregation when the plasma is clouded due to hyperlipidemia. Thus, in the present study, we measured platelet aggregation using a SFP aggregometer as it is not affected by the turbidity of plasma. The method is also easy as the preparation of platelets by centrifugation is unnecessary. Additionally, generally results obtained using the SFP method correlate well to the results obtained by the light transmission method .
During the development of atherosclerosis, the interaction between platelets and the vascular wall is critical. When the vascular walls are damaged, platelets adhere to the subendothelial surface containing collagen fibers and aggregate , . Platelet sensitivity is enhanced with hypercholesterolemia in rabbits and human –. Son et al. reported that the platelet aggregation in the hypercholesterolemic rabbit was induced by a low concentration of collagen . In the present study, platelet aggregability in hypercholesterolemic rabbits was also enhanced, and this hyper-reactivity was maintained for up to 10 weeks when fed a 0.5% cholesterol diet. The correlation between the serum TC concentration and the PATI was significant; the higher the serum TC, the lower the PATI. It is known that lowering of the serum TC attenuates platelet aggregation as well as atheroma formation . Cilostazol inhibits platelet aggregation by various agonists, in particular, it strongly inhibits platelet aggregation induced by collagen , one of the major components of the subendothelium. The inhibitory effect of cilostazol on platelet aggregation was maintained throughout the duration of this study. Thus, the anti-atherosclerotic effect of cilostazol might partly result from its sustained anti-platelet effect.
In summary, cilostazol improved lipid levels in serum and atherosclerotic aorta and inhibited the platelet aggregation detected using a SFP whole blood aggregometer in hypercholesterolemic rabbits. Cilostazol may be useful to prevent atherosclerotic progression through its anti-platelet effect and help to improve lipid abnormalities in hypercholesterolemic patients.
Materials and Methods
Seven-week-old male rabbits (New Zealand White) were purchased from Kitayama Labes (Nagano, Japan). To minimize the number of the animals used, the rabbits were washed out for 2 weeks between the first platelet aggregation study with a normal cholesterol diet and the second aggregation study with 0.5% cholesterol diet. Rabbits were fed each particular diet at 100 g/day/animal. All experimental procedures were performed in accordance with the Guidelines for Animal Care and Use of Otsuka Pharmaceutical Co., Ltd. The ethics committee specifically approved this study.
Design of Experiments
We first evaluated the platelet aggregation in rabbits fed a normal diet in the presence or absence of cilostazol, and then all the rabbits were fed the normal diet for 2 weeks to wash out the drug. Next, the platelet aggregation was evaluated in rabbits fed a high cholesterol diet. Finally, we evaluated the atherosclerotic area in aorta and the lipids in the serum and aorta. Using the combined results from the dual study, the evaluation of the atherosclerotic area was carried out.
The SFP whole blood aggregometer was from Mebanix Co., Ltd. (WBA analyzer, Yokohama, Japan). Cilostazol was synthesized at Otsuka Pharmaceutical Co., Ltd. Collagen was purchased from Nycomed Arzneimittel Gmbh. (Munchen, Germany) and sodium citrate from Sysmex (Kobe, Japan).
Measurement of Platelet Aggregation by SFP Aggregometer
Measurement of platelet aggregation with the SFP aggregometer was carried out according to the method previously described . Briefly, blood was collected from animals into plastic syringes containing sodium citrate at a final concentration of 0.38%. Suspensions of collagen were prepared at 10 times the final concentrations at 4°C. Four reaction tubes containing 200 µL aliquots of whole blood with a stirring bar were placed in the incubation chamber at 37°C. The reaction tubes were pre-incubated for 1 min at 37°C, and then 22.2 µL each of four concentrations of collagen were added. Five minutes thereafter, the filter-unit syringe with a screen micro-sieve was used to suck the blood samples. A pressure sensor was connected to the syringe. A negative pressure of –130 mmHg was set as 100% and 0 mmHg as 0%. The platelet aggregation of each reaction tube was determined as the pressure rate (%). The concentration of agonist causing a 50% change of pressure rate was calculated and expressed as the platelet aggregatory threshold index (PATI).
Evaluation of Cilostazol on Platelet Aggregation
We firstly evaluated the platelet aggregation in rabbits fed a normal diet. Platelet aggregation was measured in twenty rabbits and the PATI (pre) before drug treatment was calculated for each animal. The rabbits were then divided into two groups (control group and cilostazol group) with eight animals per group, and four animals were excluded because of an outlier PATI. The PATI (post) was measured 1 week after drug treatment, then, all the rabbits were fed the normal diet for 2 weeks to wash out the drug. Next, the platelet aggregation was evaluated in rabbits fed a 0.5% cholesterol diet. The total cholesterol in serum was measured before and after feeding the 0.5% cholesterol diet for a week. After feeding the 0.5% cholesterol diet for 1 week, platelet aggregation was determined as the PATI (pre) for the high cholesterol diet before drug treatment. Ten rabbits were excluded since the serum TC level was too high (>700 mg/dL) or too low (<300 mg/dL) or because of the outlier PATI, and the remaining animals were allocated into two groups (control group and cilostazol group) with five animals per group. A 0.5% cholesterol diet and 0.5% cholesterol plus 0.3% cilostazol diet were fed to the control group and the cilostazol group, respectively for 10 weeks. The platelet aggregation was measured and the PATI (post) 1 week and 10 weeks after drug treatment was calculated for the rabbits fed a high cholesterol diet.
Measurement of Serum Lipids and other Biomarkers
For the rabbits fed the high cholesterol diet, the blood was collected before and 2, 4, 6, 8 and 10 weeks after drug treatment, and the serum was obtained by centrifuging it at 2000×g for 10 minutes at room temperature. Total cholesterol, TG, FC, PL and HDL-C were measured as serum lipids, and GOT, GPT and ALP were measured as indices of hepatic functions and CRP was used as an index of inflammation. Serum lipids excluding FC, and GOT, GPT and ALP were measured by the multi-function automatic analyzer system (BiOLis 24i, Tokyo Boeki Machinery Ltd, Tokyo, Japan). Serum FC was measured using a multi-plate reader (Soft MAX Pro, Spectra MAX 190, Molecular Devices, CA, USA) using reagents for the BiOLis 24i. Serum CRP was measured by an enzyme-linked immunosorbent assay kit (Shibayagi, Gunma, Japan). Lipoproteins were analyzed by HPLC from 10 week serum samples. Serum was fractionated by gel chromatography using a column for lipoprotein analyses (TSKgel LipopropakXL, Tosoh, Japan). After gel filtration, lipoprotein was colored with TG reaction liquid in reaction coils, and the absorbance at 600 nm was monitored, and the elution pattern was recorded.
Measurement of Atherosclerotic Areas
The analysis of the atherosclerotic lesion was performed by Daugherty’s method with a slight modification . Following the last platelet aggregation study, rabbits were anesthetized by an injection of pentobarbital sodium (40 mg/mL at volume of 1 mL/kg animal) into the ear vein and were held on an experimental plate and their body hair was shaved. The abdomen and chest were opened, and then blood (60 mL) was collected from the abdominal vein. The aorta was perfused with ice-cold saline. The length of the aorta from the origin of the aortic arch to a femoral artery bifurcation was measured, and the aorta was excised and placed in cold saline. The aorta was cut into two regions at the diaphragm, i.e. the thoracic aorta including the arch and the abdominal aorta, and was trimmed to remove extraneous tissues under the stereomicroscope (SMZ800, Nikon, Tokyo, Japan), then longitudinally incised, and the intimal sides were exposed. The aortas were pinned on black rubber plates and photographed with a digital camera (D80, Nikon, Tokyo, Japan). The whole intimal and atherosclerotic areas were analyzed using image analyzers (Photoshop, Adobe Systems, Tokyo, Japan and WinROOF, Mitani Corporation, Tokyo, Japan). The ratio of the atherosclerotic area to the whole intimal area was calculated. Plaque areas of unstained aortas were measured in the present study because the plaque areas strongly correlated with the Sudan IV staining areas in the preliminary study (correlation coefficient: r = 0.9898).
Measurement of Aortic Lipids
After obtaining the photograph, the thoracic aorta was further separated into the arch and the residual thoracic aorta. The wet weights of the aortas (arch, thoracic aorta, and abdominal aorta) were weighed by an electronic balance (CP225D, Sartorius, Tokyo, Japan). The aortas were chopped into fine pieces. The extraction liquid (chloroform/methanol (2∶1, v/v)) was added to the chopped arteries, and they were homogenized by a digital homogenizer (As-one, Osaka, Japan). The homogenates were centrifuged at 800×g for 10 minutes. The upper-layer solution was transferred into another tube and mixed with 0.36 M CaCl2/50% methanol. The mixture was centrifuged at 800×g for 10 minutes, and this washing procedure was repeated twice. The 100 µL aliquot of the solution used to extract lipids was dried with 50% Triton X-100 in chloroform on a dry-block bath (As-one, Osaka, Japan). Isopropanol was added to the dried sample. Lipids (TC, TG, FC and PL) in the samples were measured as serum lipids.
Histochemical Staining of the Aortic Cross Section
Proximal ascending aortas were fixed with 10% neutral buffered formalin, embedded in paraffin, sectioned at 3 µm and adhered to APS coated slides. Sections were stained with an automatic immunohistochemical staining system (Venatana HX system Discovery, Roche-Diagnostics) using a mouse monoclonal antibody against rabbit macrophage, RAM11 (1∶200, Dako). Additionally, the same section was stained by the Elastica-van Gieson method.
For the PATI values, lipids in the aorta and the rate of RAM11 positive cells, the differences between the control group and the cilostazol group were statistically analyzed by a t-test. For serum lipids, the differences between two groups were statistically analyzed by repeated measures analysis of variance (ANOVA). The rate of the atherosclerotic area was statistically analyzed by using two-way ANOVA. Factors included in the ANOVA model were group and time interaction. The correlations between the serum TC concentrations and PATI values, the serum TC and serum TG, the plaque areas and the Sudan IV staining areas were evaluated using Pearson’s correlation coefficient and correlation coefficient test. Values were expressed as means ± S.D. A p-value <0.05 was considered significant. Analyses were performed using the SAS software (release 9.1, SAS Institute Japan, Tokyo, Japan).
Conceived and designed the experiments: HI GM KN. Performed the experiments: HI KU YM AH CN MN. Analyzed the data: HI. Contributed reagents/materials/analysis tools: KH HI. Wrote the paper: HI.
- 1. Ross R (1999) Atherosclerosis–an inflammatory disease. N Engl J Med 340: 115–126.R. Ross1999Atherosclerosis–an inflammatory disease.N Engl J Med340115126
- 2. Sener A, Ozsavci D, Oba R, Demirel GY, Uras F, et al. (2005) Do platelet apoptosis, activation, aggregation, lipid peroxidation and platelet-leukocyte aggregate formation occur simultaneously in hyperlipidemia? Clin Biochem 38: 1081–1087.A. SenerD. OzsavciR. ObaGY DemirelF. Uras2005Do platelet apoptosis, activation, aggregation, lipid peroxidation and platelet-leukocyte aggregate formation occur simultaneously in hyperlipidemia?Clin Biochem3810811087
- 3. Son DJ, Lee HW, Shin HW, Lee JJ, Yoo HS, et al. (2008) Enhanced release of sphingosine-1-phosphate from hypercholesterolemic platelets: role in development of hypercholesterolemic atherosclerosis. Prostaglandins Leukot Essent Fatty Acids 78: 383–390.DJ SonHW LeeHW ShinJJ LeeHS Yoo2008Enhanced release of sphingosine-1-phosphate from hypercholesterolemic platelets: role in development of hypercholesterolemic atherosclerosis.Prostaglandins Leukot Essent Fatty Acids78383390
- 4. Davì G, Patrono C (2007) Platelet activation and atherothrombosis. N Engl J Med 357: 2482–2494.G. DavìC. Patrono2007Platelet activation and atherothrombosis.N Engl J Med35724822494
- 5. Born GV, Hume M (1967) Effects of the numbers and sizes of platelet aggregates on the optical density of plasma. Nature 215: 1027–1029.GV BornM. Hume1967Effects of the numbers and sizes of platelet aggregates on the optical density of plasma.Nature21510271029
- 6. Cardinal DC, Flower RJ (1980) The electronic aggregometer: a novel device for assessing platelet behavior in blood. J Pharmacol Methods 3: 135–158.DC CardinalRJ Flower1980The electronic aggregometer: a novel device for assessing platelet behavior in blood.J Pharmacol Methods3135158
- 7. Ozeki Y, Sudo T, Toga K, Nagamura Y, Ito H, et al. (2001) Characterization of whole blood aggregation with a new type of aggregometer by a screen filtration pressure method. Thromb Res 101: 65–72.Y. OzekiT. SudoK. TogaY. NagamuraH. Ito2001Characterization of whole blood aggregation with a new type of aggregometer by a screen filtration pressure method.Thromb Res1016572
- 8. Sudo T, Ito H, Ozeki Y, Kimura Y (2001) Estimation of anti-platelet drugs on human platelet aggregation with a novel whole blood aggregometer by a screen filtration pressure method. Br J Pharmacol 133: 1396–1404.T. SudoH. ItoY. OzekiY. Kimura2001Estimation of anti-platelet drugs on human platelet aggregation with a novel whole blood aggregometer by a screen filtration pressure method.Br J Pharmacol13313961404
- 9. Kambayashi J, Liu Y, Sun B, Shakur Y, Yoshitake M, et al. (2003) Cilostazol as a unique antithrombotic agent. Curr Pharm Des 9: 2289–2302.J. KambayashiY. LiuB. SunY. ShakurM. Yoshitake2003Cilostazol as a unique antithrombotic agent.Curr Pharm Des922892302
- 10. Matsumoto M (2005) Cilostazol in secondary prevention of stroke: impact of the Cilostazol Stroke Prevention Study. Atheroscler. pp. 33–40.M. Matsumoto2005Cilostazol in secondary prevention of stroke: impact of the Cilostazol Stroke Prevention Study.Atheroscler3340
- 11. Kimura Y, Tani T, Kanbe T, Watanabe K (1985) Effect of cilostazol on platelet aggregation and experimental thrombosis. Arzneimittelforschung 35: 1144–1149.Y. KimuraT. TaniT. KanbeK. Watanabe1985Effect of cilostazol on platelet aggregation and experimental thrombosis.Arzneimittelforschung3511441149
- 12. Kohda N, Tani T, Nakayama S, Adachi T, Marukawa K, et al. (1999) Effect of cilostazol, a phosphodiesterase III inhibitor, on experimental thrombosis in the porcine carotid artery. Thromb Res 96: 261–268.N. KohdaT. TaniS. NakayamaT. AdachiK. Marukawa1999Effect of cilostazol, a phosphodiesterase III inhibitor, on experimental thrombosis in the porcine carotid artery.Thromb Res96261268
- 13. Lee JH, Oh GT, Park SY, Choi JH, Park JG, et al. (2005) Cilostazol reduces atherosclerosis by inhibition of superoxide and tumor necrosis factor-alpha formation in low-density lipoprotein receptor-null mice fed high cholesterol. J Pharmacol Exp Ther 313: 502–509.JH LeeGT OhSY ParkJH ChoiJG Park2005Cilostazol reduces atherosclerosis by inhibition of superoxide and tumor necrosis factor-alpha formation in low-density lipoprotein receptor-null mice fed high cholesterol.J Pharmacol Exp Ther313502509
- 14. Takase H, Hashimoto A, Okutsu R, Hirose Y, Ito H, et al. (2007) Anti-atherosclerotic effect of cilostazol in apolipoprotein-E knockout mice. Arzneimittelforschung 57: 185–191.H. TakaseA. HashimotoR. OkutsuY. HiroseH. Ito2007Anti-atherosclerotic effect of cilostazol in apolipoprotein-E knockout mice.Arzneimittelforschung57185191
- 15. Yoshikawa T, Mitani K, Kotosai K, Nozako M, Miyakoda G, et al. (2008) Antiatherogenic effects of cilostazol and probucol alone, and in combination in low density lipoprotein receptor-deficient mice fed with a high fat diet. Horm Metab Res 40: 473–478.T. YoshikawaK. MitaniK. KotosaiM. NozakoG. Miyakoda2008Antiatherogenic effects of cilostazol and probucol alone, and in combination in low density lipoprotein receptor-deficient mice fed with a high fat diet.Horm Metab Res40473478
- 16. Tani T, Uehara K, Sudo T, Marukawa K, Yasuda Y, et al. (2000) Cilostazol, a selective type III phosphodiesterase inhibitor, decreases triglyceride and increases HDL cholesterol levels by increasing lipoprotein lipase activity in rats. Atherosclerosis 152: 299–305.T. TaniK. UeharaT. SudoK. MarukawaY. Yasuda2000Cilostazol, a selective type III phosphodiesterase inhibitor, decreases triglyceride and increases HDL cholesterol levels by increasing lipoprotein lipase activity in rats.Atherosclerosis152299305
- 17. Maeda E, Yoshino G, Nagata K, Matsuba K, Matsushita M, et al. (1993) Effect of cilostazol on triglyceride metabolism in rats. Curr Ther Res 54: 420–424.E. MaedaG. YoshinoK. NagataK. MatsubaM. Matsushita1993Effect of cilostazol on triglyceride metabolism in rats.Curr Ther Res54420424
- 18. Nakamura N, Hamazaki T, Johkaji H, Minami S, Yamazaki K, et al. (2003) Effects of cilostazol on serum lipid concentrations and plasma fatty acid composition in type 2 diabetic patients with peripheral vascular disease. Clin Exp Med. 2: 180–184.N. NakamuraT. HamazakiH. JohkajiS. MinamiK. Yamazaki2003Effects of cilostazol on serum lipid concentrations and plasma fatty acid composition in type 2 diabetic patients with peripheral vascular disease. Clin Exp Med.2180184
- 19. Dawson DL, Cutler BS, Meissner MH, Strandness DE Jr (1998) Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial. Circulation 98: 678–686.DL DawsonBS CutlerMH MeissnerDE Strandness Jr1998Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial.Circulation98678686
- 20. Elam MB, Heckman J, Crouse JR, Hunninghake DB, Herd JA, et al. (1998) Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication. Arterioscler Thromb Vasc Biol. 18: 1942–1947.MB ElamJ. HeckmanJR CrouseDB HunninghakeJA Herd1998Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication. Arterioscler Thromb Vasc Biol.1819421947
- 21. Toyota T, Oikawa S, Abe R, Sano R, Suzuki N, et al. (2001) Effect of Cilostazol on Lipid, Uric Acid and Glucose Metabolism in Patients with Impaired Glucose Tolerance or Type 2 Diabetes Mellitus: A Double-Blind, Placebo-Controlled Study. Clin Drug Invest. 21: 325–335.T. ToyotaS. OikawaR. AbeR. SanoN. Suzuki2001Effect of Cilostazol on Lipid, Uric Acid and Glucose Metabolism in Patients with Impaired Glucose Tolerance or Type 2 Diabetes Mellitus: A Double-Blind, Placebo-Controlled Study. Clin Drug Invest.21325335
- 22. Rizzo M, Corrado E, Patti AM, Rini GB, Mikhailidis DP (2011) Cilostazol and atherogenic dyslipidemia: a clinically relevant effect? Expert Opin Pharmacother. 12: 647–655.M. RizzoE. CorradoAM PattiGB RiniDP Mikhailidis2011Cilostazol and atherogenic dyslipidemia: a clinically relevant effect? Expert Opin Pharmacother.12647655
- 23. Brousseau ME, Hoeg JM (1999) Transgenic rabbits as models for atherosclerosis research. J Lipid Res 40: 365–375.ME BrousseauJM Hoeg1999Transgenic rabbits as models for atherosclerosis research.J Lipid Res40365375
- 24. Rizzo M, Taylor JM, Barbagallo CM, Berneis K, Blanche PJ, et al. (2004) Effects on Lipoprotein Subclasses of Combined Expression of Human Hepatic Lipase and Human apoB in Transgenic Rabbits. Arterioscler Thromb Vasc Biol 24: 141–146.M. RizzoJM TaylorCM BarbagalloK. BerneisPJ Blanche2004Effects on Lipoprotein Subclasses of Combined Expression of Human Hepatic Lipase and Human apoB in Transgenic Rabbits.Arterioscler Thromb Vasc Biol24141146
- 25. Hirano K, Ikeda Y, Zaima N, Sakata Y, Matsumiya G (2008) Triglyceride deposit cardiomyovasculopathy. N Engl J Med 359: 2396–2398.K. HiranoY. IkedaN. ZaimaY. SakataG. Matsumiya2008Triglyceride deposit cardiomyovasculopathy.N Engl J Med35923962398
- 26. Hokland BM, Slotte JP, Bierman EL, Oram JF (1993) Cyclic AMP stimulates efflux of intracellular sterol from cholesterol-loaded cells. J Biol Chem 268: 25343–25349.BM HoklandJP SlotteEL BiermanJF Oram1993Cyclic AMP stimulates efflux of intracellular sterol from cholesterol-loaded cells.J Biol Chem2682534325349
- 27. Girman CJ, Rhodes T, Mercuri M, Pyörälä K, Kjekshus J, et al. (2004) The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am J Cardiol 93: 136–141.CJ GirmanT. RhodesM. MercuriK. PyöräläJ. Kjekshus2004The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS).Am J Cardiol93136141
- 28. Amarenco P, Goldstein LB, Callahan A 3rd, Sillesen H, Hennerici MG, et al (2009) Baseline blood pressure, low- and high-density lipoproteins, and triglycerides and the risk of vascular events in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Atherosclerosis 204: 515–520.Amarenco P, Goldstein LB, Callahan A 3rd, Sillesen H, Hennerici MG, et al2009Baseline blood pressure, low- and high-density lipoproteins, and triglycerides and the risk of vascular events in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.Atherosclerosis204515520
- 29. Gotto AM Jr (2002) High-density lipoprotein cholesterol and triglycerides as therapeutic targets for preventing and treating coronary artery disease. Am Heart J 144: S33–42.AM Gotto Jr2002High-density lipoprotein cholesterol and triglycerides as therapeutic targets for preventing and treating coronary artery disease.Am Heart J144S3342
- 30. Aronis A, Madar Z, Tirosh O (2008) Lipotoxic effects of triacylglycerols in J774.2 macrophages. Nutrition 24: 167–176.A. AronisZ. MadarO. Tirosh2008Lipotoxic effects of triacylglycerols in J774.2 macrophages.Nutrition24167176
- 31. Minami N, Suzuki Y, Yamamoto M, Kihira H, Imai E, et al. (1997) Inhibition of shear stress-induced platelet aggregation by cilostazol, a specific inhdbitor of cGMP-inhibited phosphodiesterase, in vitro and ex vivo. Life Sciences 61: PL383–389.N. MinamiY. SuzukiM. YamamotoH. KihiraE. Imai1997Inhibition of shear stress-induced platelet aggregation by cilostazol, a specific inhdbitor of cGMP-inhibited phosphodiesterase, in vitro and ex vivo.Life Sciences61PL383389
- 32. Park SY, Lee JH, Kim YK, Kim CD, Rhim BY, et al. (2005) Cilostazol prevents remnant lipoprotein particle-induced monocyte adhesion to endothelial cells by suppression of adhesion molecules and monocyte chemoattractant protein-1 expression via lectin-like receptor for oxidized low-density lipoprotein receptor activation. J Pharmacol Exp Ther 312: 1241–1248.SY ParkJH LeeYK KimCD KimBY Rhim2005Cilostazol prevents remnant lipoprotein particle-induced monocyte adhesion to endothelial cells by suppression of adhesion molecules and monocyte chemoattractant protein-1 expression via lectin-like receptor for oxidized low-density lipoprotein receptor activation.J Pharmacol Exp Ther31212411248
- 33. Okutsu R, Yoshikawa T, Nagasawa M, Hirose Y, Takase H, et al. (2009) Cilostazol inhibits modified low-density lipoprotein uptake and foam cell formation in mouse peritoneal macrophages. Atherosclerosis 204: 405–411.R. OkutsuT. YoshikawaM. NagasawaY. HiroseH. Takase2009Cilostazol inhibits modified low-density lipoprotein uptake and foam cell formation in mouse peritoneal macrophages.Atherosclerosis204405411
- 34. Ishizaka N, Taguchi J, Kimura Y, Ikari Y, Aizawa T, et al. (1999) Effects of a single local administration of cilostazol on neointimal formation in balloon-injured rat carotid artery. Atherosclerosis 142: 41–46.N. IshizakaJ. TaguchiY. KimuraY. IkariT. Aizawa1999Effects of a single local administration of cilostazol on neointimal formation in balloon-injured rat carotid artery.Atherosclerosis1424146
- 35. Iba T, Kidokoro A, Fukunaga M, Takuhiro K, Ouchi M, et al. (2006) Comparison of the protective effects of type III phosphodiesterase (PDE3) inhibitor (cilostazol) and acetylsalicylic acid on intestinal microcirculation after ischemia reperfusion injury in mice. Shock 26: 522–526.T. IbaA. KidokoroM. FukunagaK. TakuhiroM. Ouchi2006Comparison of the protective effects of type III phosphodiesterase (PDE3) inhibitor (cilostazol) and acetylsalicylic acid on intestinal microcirculation after ischemia reperfusion injury in mice.Shock26522526
- 36. Mori D, Ishii H, Kojima C, Nitta N, Nakajima K, et al. (2007) Cilostazol inhibits monocytic cell adhesion to vascular endothelium via up-regulation of cAMP. J Atheroscler Thromb 14: 213–218.D. MoriH. IshiiC. KojimaN. NittaK. Nakajima2007Cilostazol inhibits monocytic cell adhesion to vascular endothelium via up-regulation of cAMP.J Atheroscler Thromb14213218
- 37. Ito H, Miyakoda G, Mori T (2004) Cilostazol inhibits platelet-leukocyte interaction by suppression of platelet activation. Platelets 15: 293–301.H. ItoG. MiyakodaT. Mori2004Cilostazol inhibits platelet-leukocyte interaction by suppression of platelet activation.Platelets15293301
- 38. Ross R, Glomset J, Harker L (1977) Response to injury and atherogenesis. Am J Pathol 86: 675–684.R. RossJ. GlomsetL. Harker1977Response to injury and atherogenesis.Am J Pathol86675684
- 39. D Shanmuganayagam, T.F Warner, C.G Krueger, J.D Reed, J.D Folts (2007) Concord grape juice attenuates platelet aggregation, serum cholesterol and development of atheroma in hypercholesterolemic rabbits. Atherosclerosis 190: 135–142.Shanmuganayagam DWarner T.FKrueger C.GReed J.DFolts J.D2007Concord grape juice attenuates platelet aggregation, serum cholesterol and development of atheroma in hypercholesterolemic rabbits.Atherosclerosis190135142
- 40. Daugherty A, Zweifel BS, Schonfeld G (1989) Probucol attenuates the development of aortic atherosclerosis in cholesterol-fed rabbits. Br J Pharmacol 98: 612–618.A. DaughertyBS ZweifelG. Schonfeld1989Probucol attenuates the development of aortic atherosclerosis in cholesterol-fed rabbits.Br J Pharmacol98612618